| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H33NO2 |
| Molecular Weight | 355.5136 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C(C)(C)C5=C(C[C@]34C)C=NO5
InChI
InChIKey=AXLOCHLTNQDFFS-BESJYZOMSA-N
InChI=1S/C23H33NO2/c1-20(2)18-7-6-15-16(21(18,3)12-14-13-24-26-19(14)20)8-10-22(4)17(15)9-11-23(22,5)25/h7,13,15-17,25H,6,8-12H2,1-5H3/t15-,16+,17+,21-,22+,23+/m1/s1
| Molecular Formula | C23H33NO2 |
| Molecular Weight | 355.5136 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AZASTENE is an inhibitor of ovarian and adrenal steroidogenesis which can be used as an interceptive agent. Its action leads to an acute, short-term, reversible progesterone withdrawal. The reduction of progesterone levels is brought about by competitive inhibition of ovarian 3beta-hydroxysteroid dehydrogenase activity.
